Evidence map›Paper›PMID 35869122›Full record

ArticleScientific reports2022

Structure-based prediction of BRAF mutation classes using machine-learning approaches.

Fanny S Krebs, Christian Britschgi, Sylvain Pradervand, Rita Achermann, Petros Tsantoulis, Simon Haefliger, Andreas Wicki, Olivier Michielin, Vincent Zoete

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 1 country.

Fanny S KrebsComputer-Aided Molecular Engineering Group, Department of Oncology UNIL-CHUV, University of Lausanne, Epalinges, Switzerland.
Christian BritschgiDepartment of Medical Oncology and Hematology, University Hospital Zurich, Comprehensive Cancer Center Zurich, University of Zurich, Zurich, Switzerland.
Sylvain PradervandCenter for Precision Oncology, Department of Oncology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland.
Rita AchermannDepartment of Radiology, Clinic of Radiology and Nuclear Medicine, University Hospital Basel, University of Basel, Basel, Switzerland.
Petros TsantoulisDepartment of Oncology, Hôpitaux Universitaires de Genève, University of Geneva, Geneva, Switzerland.
Simon HaefligerDepartment of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Andreas WickiDepartment of Medical Oncology and Hematology, University Hospital Zurich, Comprehensive Cancer Center Zurich, University of Zurich, Zurich, Switzerland.
Olivier MichielinMolecular Modelling Group, SIB Swiss Institute of Bioinformatics, Lausanne, Switzerland.
Vincent ZoeteComputer-Aided Molecular Engineering Group, Department of Oncology UNIL-CHUV, University of Lausanne, Epalinges, Switzerland. Vincent.zoete@unil.ch.
SIB Swiss Institute of Bioinformatics · CHUniversity of Lausanne · CHUniversity of Zurich · CHUniversity Hospital of Basel · CHUniversity Hospital of Bern · CHUniversity of Geneva · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The BRAF kinase is attracting a lot of attention in oncology as alterations of its amino acid sequence can constitutively activate the MAP kinase signaling pathway, potentially contributing to the malignant transformation of the cell but at the same time rendering it sensitive to targeted therapy. Several pathologic BRAF variants were grouped in three different classes (I, II and III) based on their effects on the protein activity and pathway. Discerning the class of a BRAF mutation permits to adapt the treatment proposed to the patient. However, this information is lacking new and experimentally uncharacterized BRAF mutations detected in a patient biopsy. To overcome this issue, we developed a new in silico tool based on machine learning approaches to predict the potential class of a BRAF missense variant. As class I only involves missense mutations of Val600, we focused on the mutations of classes II and III, which are more diverse and challenging to predict. Using a logistic regression model and features including structural information, we were able to predict the classes of known mutations with an accuracy of 90%. This new and fast predictive tool will help oncologists to tackle potential pathogenic BRAF mutations and to propose the most appropriate treatment for their patients.

Indexed as

MAP Kinase Signaling SystemProto-Oncogene Proteins B-rafHumansMachine LearningMutationMutation, MissenseBRAF protein, humanProto-Oncogene Proteins B-raf

Identifiers

PMID35869122
PMCPMC9307832
OpenAlexW4286470788

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.